Recently, ALRN-6924, a dual HDM/HDMX inhibitor developed by Aileron Therapeutics, revealed improved survival in mice bearing wild-type p53 acute myeloid leukemia xenografts [74], whereas p53-mutant leukemia cell lines HL60 and Kasumi-1 were insensitive to the peptide [74]. The gene discussed is TP53; the disease is acute myeloid leukemia.